Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Botulism

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adeno-Associated Virus Type 9-Mediated Gene Therapy of Choline Acetyltransferase-Deficient Mice.

Human gene therapy·2024

Same author

Recessive congenital myasthenic syndrome caused by a homozygous mutation in SYT2 altering a highly conserved C-terminal amino acid sequence.

American journal of medical genetics. Part A·2020

Same author

Presynaptic congenital myasthenic syndrome with altered synaptic vesicle homeostasis linked to compound heterozygous sequence variants in RPH3A.

Molecular genetics & genomic medicine·2018

Same author

Presynaptic congenital myasthenic syndrome with a homozygous sequence variant in LAMA5 combines myopia, facial tics, and failure of neuromuscular transmission.

American journal of medical genetics. Part A·2017

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Presynaptic Congenital Myasthenic Syndromes.

Ricardo A Maselli¹

¹Department of Neurology, University of California Davis, Sacramento, California, USA.

|July 1, 2026

Summary

This summary is machine-generated.

Presynaptic congenital myasthenic syndromes (CMS) impair acetylcholine release, causing muscle weakness and potential autonomic dysfunction. While gene mutations are the cause, treatments focus on managing respiratory issues and symptoms, with gene therapy still in preclinical stages.

Keywords:

acetylcholine choline acetyltransferase choline transporter congenital myasthenic syndromes neuromuscular junction presynaptic

More Related Videos

Measuring Neuromuscular Junction Functionality

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

Related Experiment Videos

Last Updated: Jul 2, 2026

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Measuring Neuromuscular Junction Functionality

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

Area of Science:

Neurology
Genetics
Molecular Biology

Background:

Presynaptic congenital myasthenic syndromes (CMS) are rare neuromuscular disorders.
They result from impaired acetylcholine (ACh) release from motor nerve terminals.
These conditions manifest as muscle weakness, fatigue, and can involve central and autonomic nervous systems.

Purpose of the Study:

To review the causes and clinical features of presynaptic CMS.
To discuss current treatment strategies and their limitations.
To highlight the potential of future gene therapies.

Main Methods:

Literature review of presynaptic CMS.
Analysis of genetic mutations causing CMS.
Summary of clinical manifestations and treatment outcomes.

Main Results:

Presynaptic CMS involves either diminished ACh in synaptic vesicles or impaired vesicle release.
Genetic mutations in ACh synthesis and release proteins are common causes.
Associated symptoms include muscle weakness, fatigue, apnea, cognitive delay, seizures, and gastrointestinal issues.

Conclusions:

Effective management of presynaptic CMS involves preventing respiratory complications and symptomatic treatment.
Pharmacological treatments offer partial relief, and some mild cases improve with age.
Gene therapy shows promise in preclinical models but is not yet clinically available.